BioSpace News Archive

Blackfynn, a company using a systematic approach that combines data, technology and disease-specific clinical expertise to develop a growing pipeline of targeted, clinical-stage therapeutics for Parkinson’s and neurodegeneration, today announced that it has entered into an agreement with an undisclosed partner to acquire rights to a Phase 3-ready drug to treat Parkinson’s.

Metabolon, Inc. has entered into to a multi-year collaborative agreement with Cleveland Clinic to provide Metabolon’s Precision Metabolomics™ services in support of drug development and related research efforts.

Elucid, a medical technology company developing AI software to enable cardiovascular disease detection, announced the publication of new clinical data in the International Journal of Cardiology.

Acadia Pharmaceuticals Inc. announced that it will participate at the following investor conferences

PPD, Inc. (Nasdaq: PPD ), a leading global contract research organization, has been awarded Defense Health Agency funds to support a five-year Research Project Award (RPA) to develop and execute an adaptive platform clinical research trial of drug interventions to treat post-traumatic stress disorder (PTSD).

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Victorian Clinical Genetic Services (VCGS), an Australian-based specialist provider of prenatal, childhood and adult genetics services, today announced that together they have developed a novel whole exome capture assay.

Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, announced today that it will host the Company’s 2020 fourth quarter and full-year earnings

Thykamine™ monotherapy achieved positive results by reaching the study’s primary endpoint with statistical significance, delivering significant improvement in skin clearance as determined by the Investigator Global Assessment (IGA)

KEY CAPITAL CORPORATION advises that it continues to work with Immunitor, its partner and Licensor, to progress further research and development of its breakthrough therapeutic vaccines, and for several unique supplements.

The American Gastroenterological Association (AGA) has officially endorsed a novel Clinical Decision Support Tool (CDST) designed for healthcare providers managing patients with IBD who need evidence-based guidance on biologic therapy selection.